The steps that India has been taking to ensure that life-saving drugs remain accessible, safe, and affordable for all Indians—and, in turn, for the global community that relies on “Made in India” pharmaceuticals.
1. A Clear Vision: National Pharmaceuticals Pricing Policy (NPPP), 2012
Central to India’s drug affordability framework is the National Pharmaceuticals Pricing Policy (NPPP), 2012, which sets out three foundational principles for regulating drug prices:
- Essentiality of Drugs: Only those medicines deemed essential—typically vital for public health—fall under direct price regulation.
- Formulation-Focused Approach: Pricing control applies to finished medicinal products (formulations) and not to raw materials or intermediates.
- Market-Based Pricing: Rather than rely on cost-based calculations, drug price ceilings are determined by prevailing market prices to foster competition and maintain accessibility.
The National Pharmaceutical Pricing Authority (NPPA) is tasked with enforcing these principles. Working under the Department of Pharmaceuticals (DoP), it notifies and revises the ceiling prices for essential drugs in accordance with the Drugs (Prices Control) Order (DPCO), 2013.
2. DPCO, 2013 and the Quest for Affordability
Under DPCO, 2013, every manufacturer producing a regulated drug formulation must issue a price list (Form-V) or supplementary list if changes arise—furnishing these details to dealers, State Drugs Controllers, and the Government. The aim is straightforward: keep retailers and, importantly, consumers informed about the maximum allowable retail prices.
As an additional transparency measure, the NPPA regularly uploads draft price calculation sheets on its website, inviting comments from industry stakeholders for a set period before finalizing the prices. This open-door policy ensures broad stakeholder participation and underscores the Government’s focus on accountability.
3. Empowering Consumers: ‘Pharma Sahi Daam’ Mobile App
Launched by the NPPA, the ‘Pharma Sahi Daam’ (PSD) mobile application is a consumer-friendly initiative designed to tackle overpricing concerns head-on:
- Free Access & Ease of Use: Available on both Android (Google Play Store) and iOS (App Store).
- Instant Price Checks: Enter the drug’s name or composition to see the corresponding ceiling price and MRP.
- Continuous Updates: Reflects the latest official price notifications.
This digital tool has become a powerful ally for patients and caregivers eager to avoid being overcharged, marking another step toward increased consumer awareness.
4. IPDMS 2.0: The Backbone of Pricing Data
A significant pillar supporting NPPA’s efforts is the Integrated Pharmaceutical Database Management System (IPDMS). Its upgraded version, IPDMS 2.0, offers:
- Real-Time Reporting: Online submission of mandatory returns and reports, ensuring data consistency.
- Market Transparency: Displays effective ceiling and retail prices regularly updated for stakeholders, including policymakers, manufacturers, and consumers.
- Efficient Oversight: Fosters better monitoring of pricing trends, helping regulators take corrective action if ceilings are breached.
5. Rising Global Profile: India’s Pharmaceutical Exports
Beyond domestic affordability, India plays a pivotal role in the global pharmaceutical supply chain. A secondary market research analysis published by Bain and Company in 2025 revealed that:
| Year | Global Rank in Value Terms | Share in Total Global Pharma Exports |
| 2023 | 11th | 3% |
Such a ranking spotlights India’s remarkable growth trajectory. Cost-competitiveness, technological strides in manufacturing, and expansive distribution networks have helped India claim a significant slice of global pharmaceutical exports.
6. Quality, Safety, and Efficacy: The Regulatory Net Widens
While affordability is essential, the Government is equally invested in maintaining quality. The Central Drugs Standard Control Organisation (CDSCO), under the Ministry of Health and Family Welfare, has rolled out a series of steps:
- Risk-Based Inspections:
- Launched in December 2022 in collaboration with State regulators.
- 905 manufacturing and testing units inspected.
- 694 actions initiated, including orders to stop production, suspend/cancel licenses, and issue warnings.
| Parameter | Figure |
| Total Units Inspected | 905 |
| Actions Taken | 694 |
| Types of Actions | Stoppage, Suspension, Cancellation, Warnings/Show-Cause |
- Revised Schedule M for GMP
- Updated premises, plant, and equipment rules (Drugs Rules, 1945) via a notification on 28.12.2023.
- Effective from 29.6.2024 for firms with turnover above ₹250 crore; extended to 31.12.2025 for smaller manufacturers.
- Barcode/QR Code Implementation
- Top 300 Brands: Must have a barcode or QR code, effective 1.8.2023, storing essential drug information (batch number, manufacturing date, expiry date).
- Active Pharmaceutical Ingredients: From 18.1.2022, every API (bulk drug) must bear QR codes at every packaging level for robust tracking.
- Holding Marketers Accountable
- Post-11.2.2020 amendment to the Drugs Rules, 1945: both manufacturer and marketer share responsibility for drug quality and compliance.
- Stricter Penalties for Spurious Drugs
- Through the 2008 amendment to the Drugs and Cosmetics Act, 1940, offences for manufacturing spurious/adulterated drugs can attract severe penalties.
- Certain offences now cognizable and non-bailable.
- Special Courts & Training Initiatives
- Several States and UTs have set up special courts to expedite trials under the Drugs and Cosmetics Act, 1940.
- Over 35,000 personnel trained since April 2023 on Good Manufacturing Practices (GMP) and related regulations.
7. The Road Ahead: Building Trust at Home and Abroad
Backed by strong policies and continuous reforms, India’s pharmaceutical industry continues to be a cornerstone of the global healthcare supply chain. Balancing affordability with uncompromising quality, the Government’s holistic approach—ranging from the National Pharmaceuticals Pricing Policy (NPPP), 2012 to risk-based inspections and GMP reforms—has showcased India’s commitment to improving healthcare access worldwide.
With the ‘Pharma Sahi Daam’ app empowering domestic consumers and IPDMS 2.0 ensuring robust market data, the national focus remains firmly on transparency and accountability. As India climbs higher in global export rankings, the synergy of policy, innovation, and regulation heralds a transformative era in which medicines are not only affordable but also exemplary in quality and safety.
India’s pharmaceutical narrative is poised to continue its upward momentum, and the world is watching—both for the cost-effective treatments it needs and for the rigorous standards consumers everywhere deserve.